A Study of LY3502970 in Healthy Participants
1期
已完成
NCT03929744
| 适应症 | Healthy |
|---|
| 分期 | 1期 |
|---|
| 申办方 | Eli Lilly and Company |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 133 人 |
|---|
| 干预（药物） | LY3502970, Atorvastatin, Simvastatin, Midazolam |
|---|
| 开始日期 | 2019年6月12日 |
|---|
| 完成日期 | 2020年11月2日 |
|---|
| 结果公布日 | 2026年7月10日 |
|---|
摘要
The main purposes of this study are to determine: * The safety of LY3502970 and any side effects that might be associated with it. * How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.
Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
Baseline through Follow-up (up to Day 42) · Participants
| Part A Placebo | 0 Participants |
|---|
| Part A 0.3 mg LY3502970 | 0 Participants |
|---|
| Part A 1 mg LY3502970 | 0 Participants |
|---|
| Part A 3 mg LY3502970 | 0 Participants |
|---|
| Part A 6 mg LY3502970 | 0 Participants |
|---|
| Part B Placebo | 0 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。